Cite
Loibl S, Rokitta D, Conrad B, et al. Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. Breast Care (Basel). 2014;9(3):169-74doi: 10.1159/000363430.
Loibl, S., Rokitta, D., Conrad, B., Harbeck, N., Wüllner, M., Warm, M., Schwedler, K., Gerber, B., Schrader, I., Eidtmann, H., Mehta, K., Fuhr, U., & von Minckwitz, G. (2014). Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. Breast care (Basel, Switzerland), 9(3), 169-74. https://doi.org/10.1159/000363430
Loibl, Sibylle, et al. "Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA." Breast care (Basel, Switzerland) vol. 9,3 (2014): 169-74. doi: https://doi.org/10.1159/000363430
Loibl S, Rokitta D, Conrad B, Harbeck N, Wüllner M, Warm M, Schwedler K, Gerber B, Schrader I, Eidtmann H, Mehta K, Fuhr U, von Minckwitz G. Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. Breast Care (Basel). 2014 Jul;9(3):169-74. doi: 10.1159/000363430. PMID: 25177258; PMCID: PMC4132235.
Copy
Download .nbib